ISS recommends MEI Pharma shareholders vote FOR merger with Infinity Pharma

Lite Strategy, Inc.

Independent proxy advisory ISS recommends voting FOR the Infinity merger at July 14 special meeting.
MEI board reiterates support, citing potential to create diversified three-program clinical pipeline.
Combined company expects key clinical data from both MEI programs by year-end 2023.
Shareholders of record as of May 24, 2023 are eligible to vote.
Alliance Advisors is proxy solicitor; Stifel and Morgan Lewis are advisors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.